Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2
Treatment with cisplatin (DDP) is one of the standard therapies used to treat non-small-cell lung cancer (NSCLC) and fundamentally causes resistance in cancer cells, which eventually poses as an obstacle to the efficacy of chemotherapy in NSCLC. Efforts are on all over the world to explore a sensiti...
Saved in:
Main Authors: | Bin Ke, Ting Wei, Yuanyuan Huang, Yuxin Gong, Gang Wu, Junfang Liu, Xiaoting Chen, Lin Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2019/7241418 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment
by: Tingwang Shi, et al.
Published: (2025-02-01) -
Biological Functions and Clinical Significance of the ABCG1 Transporter
by: Stanislav Kotlyarov, et al.
Published: (2024-12-01) -
Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway
by: Lile Wang, et al.
Published: (2024-01-01) -
Interleukin-7 and Immunosenescence
by: Vanloan Nguyen, et al.
Published: (2017-01-01) -
LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress
by: Peng Ma, et al.
Published: (2022-01-01)